(Q37851520)

24 August 2017

1 reference

title

Evaluating the role of IL-12 based therapies in ovarian cancer: a review of the literature (English)

1 reference

24 August 2017

1 reference

Jenny M Whitworth

1

1 reference

24 August 2017

Ronald D Alvarez

series ordinal

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

11 March 2011

1 reference

Expert Opinion on Biological Therapy

24 August 2017

published in

1 reference

24 August 2017

volume

11

1 reference

24 August 2017

issue

6

1 reference

24 August 2017

page(s)

751-762

1 reference

Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Interleukin 12: a key modulator of immune function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon-gamma by natural killer cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Regulation of human cytolytic lymphocyte responses by interleukin-12

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Enhancing effect of natural killer cell stimulatory factor (NKSF/interleukin-12) on cell-mediated cytotoxicity against tumor-derived and virus-infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Inhibition of angiogenesis in vivo by interleukin 12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Interleukin-12: biological properties and clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Is ascitic fluid interleukin-12 an independent prognostic factor in ovarian cancer? The necessity of correction milligram P values for multiple comparisons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Receptors for HLA class-I molecules in human natural killer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Interleukin-12-mediated tumoricidal activity of patient lymphocytes in an autologous in vitro ovarian cancer assay system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Treatment of malignant ascites due to recurrent/refractory ovarian cancer: the use of interferon-α or interferon-α plus chemotherapy in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Novel therapies for recurrent ovarian cancer management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Immunotherapy opportunities in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Interleukin 12 augments natural killer-cell mediated cytotoxicity in hairy cell leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Antitumor and antimetastatic activity of interleukin 12 against murine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Multiple effects on peripheral hematology following administration of recombinant human interleukin 12 to nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Review: novel nonviral delivery approaches for interleukin-12 protein and gene systems: curbing toxicity and enhancing adjuvant activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Biodegradable polymer-based interleukin-12 gene delivery: role of induced cytokines, tumor infiltrating cells and nitric oxide in anti-tumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Intratumoral delivery of IL-12 gene by polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Plasmid DNA encoding human carcinoembryonic antigen (CEA) adsorbed onto cationic microparticles induces protective immunity against colon cancer in CEA-transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Paracrine release of IL-12 stimulates IFN-gamma production and dramatically enhances the antigen-specific T cell response after vaccination with a novel peptide-based cancer vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Characterization of cytokine-encapsulated controlled-release microsphere adjuvants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Intratumoral IL-12 and TNF-alpha-loaded microspheres lead to regression of breast cancer and systemic antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Human inflammatory cells within the tumor microenvironment of lung tumor xenografts mediate tumor growth suppression in situ that depends on and is augmented by interleukin-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Cytokine immunotherapy of cancer with controlled release biodegradable microspheres in a human tumor xenograft/SCID mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Cytotoxic T lymphocyte response against non-immunoselected tumor antigens predicts the outcome of gene therapy with IL-12-transduced tumor cell vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Long-lasting anti-metastatic efficiency of interleukin 12-encoding plasmid DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

IL-12 plasmid-enhanced DNA vaccination against carcinoembryonic antigen (CEA) studied in immune-gene knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Plasmids encoding membrane-bound IL-4 or IL-12 strongly costimulate DNA vaccination against carcinoembryonic antigen (CEA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Tumor regression by repeated intratumoral delivery of water soluble lipopolymers/p2CMVmIL-12 complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Liposomes as carriers for vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Liposomal vaccines: clinical status and immunological presentation for humoral and cellular immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Intratracheal administration of interleukin 12 plasmid-cationic lipid complexes inhibits murine lung metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

The preparation, characterization, and evaluation of cationic microparticles for DNA vaccine delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Advantages and limitations of particle‐mediated transfection (gene gun) in cancer immuno‐gene therapy using IL‐10, IL‐12 or B7‐1 in murine tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Intravenous cytokine gene delivery by lipid-DNA complexes controls the growth of established lung metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Antitumoral effect of interleukin-12-secreting fibroblasts in a mouse model of ovarian cancer: implications for the use of ovarian cancer biopsy-derived fibroblasts as a vehicle for regional gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Cotransduction of CCL27 gene can improve the efficacy and safety of IL-12 gene therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Treatment of disseminated ovarian cancer using nonviral interleukin-12 gene therapy delivered intraperitoneally

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

The toxicology of interleukin-12: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Intraperitoneal human recombinant interferon alpha-2b in minimal residual ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566854

10.1517/14712598.2011.566854

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference